VIA EDGAR

Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Joshua Gorsky

Re: Cellectar Biosciences, Inc. Registration Statement on Form S-1 Filed January 29, 2025 File No. 333-284580

Ladies and Gentlemen:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), hereby requests that the effective date of the Company's Registration Statement on Form S-1 (Registration No. 333-284580), be accelerated so that the Registration Statement will become effective at 5:00 p.m. on February 6, 2025, or as soon as practicable thereafter.

The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Kostian Ciko (212-839-5450 or <u>kciko@sidley.com</u>). Thank you for your assistance with these matters.

Very truly yours,

cc:

CELLECTAR BIOSCIENCES, INC.

By: /s/ Chad J. Kolean Chad J. Kolean, Chief Financial Officer

> James V. Caruso Asher M. Rubin Istvan A. Hajdu Kostian Ciko

February 4, 2025